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In a randomized controlled study in patients with suspected NSCLC, 
who were scheduled to surgery after CSW, van Tinteren et al (9) tested 
whether PET reduces number of futile thoracotomies. They found that 
addition of PET to CSW prevented unnecessary surgery in one out of 
ﬁve patients with suspected NSCLC.
Despite the additional cost of adding PET to the CSW, there is an 
overall lower total cost of care for the group undergoing CSW and PET 
compared with a group undergoing CSW alone (10, 11). Dietlein et 
al (10) studied whether WB PET plays an effective role in metastasis 
workup of asymptomatic or node-negative (at CT) pts. They concluded 
the implementation of WB PET with a full ring of detectors in the 
preoperative staging of patients with NSCLC and normal-sized lymph 
nodes is clearly cost-effective. However, because of potential false-
positive results from PET, more invasive procedures, such as mediasti-
noscopy, may be needed to conﬁrm suspected disease.
Whole Body MR Imaging 
Development of a rolling platform (BodySURF, MR-Innonvation, 
Essen, Germany) mounted on top of the scanner table overcame ﬁeld 
of view restrictions and extended the scan range in the z-axis with-
out repositioning (12). Additional improvement was achieved by the 
introduction of parallel imaging techniques (PAT). The basic principle 
of this is the use of the spatial information from different elements 
of multiple independent radiofrequency receiver coils to reconstruct 
the image. This process subsequently reduces scan time and results 
in shorter overall examination times without compromising spatial or 
temporal resolution (13). The recent introduction of WB scanners using 
a system of multiple phase-array coils covering the entire body as a 
matrix allows (in combination with automated table movement) WB 
imaging with PAT in all three spatial dimensions at t total ﬁeld of view 
of 205 cm (14).
Antoch et al (15) performed a study to determine the staging accuracies 
of both WB PET/CT and WB MRI for different malignant diseases. In 
their study, they concluded that the feasibility and diagnostic accuracy 
of the WB staging strategies of PET/CT and MRI are established. Su-
perior performance in overall TNM staging suggests the use of 18F FDG 
PET/CT as a possible ﬁrst-line modality for WB tumor staging.
Yi et al (16) compared prospectively the diagnostic efﬁcacies for 
determining TNM stages of integrated PET/CT and 3T whole-body MR 
imaging (WB MRI) in non-small cell lung cancer (NSCLC). Fourteen 
(M1, 9%) of 149 patients had 23 metastatic lesions. Accuracy for 
detecting metastases was 93% (138 of 149) at PET/CT, whereas that 
at WB MRI was 95% (142 of 149) (p = 0.388). WB MRI was more 
useful for detecting brain metastases, whereas PET/CT for soft-tissue 
metastases. They concluded that both 3T WB MRI and PET/CT appear 
to provide acceptable accuracy and comparable efﬁcacy in NSCLC 
staging, but in M stage determination, they have different advantages 
from each other. Therefore, whole body MR/PET may be the future 
imaging modality for NSCLC staging.  
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